Literature DB >> 15679468

Molecular characterization of human xanthine oxidoreductase: the enzyme is grossly deficient in molybdenum and substantially deficient in iron-sulphur centres.

Benjamin L J Godber1, Guenter Schwarz, Ralf R Mendel, David J Lowe, Robert C Bray, Robert Eisenthal, Roger Harrison.   

Abstract

XOR (xanthine oxidoreductase) purified from human milk was shown to contain 0.04 atom of Mo and 0.09 molecule of molybdopterin/subunit. On the basis of UV/visible and CD spectra, the human enzyme was approx. 30% deficient in iron-sulphur centres. Mo(V) EPR showed the presence of a weak rapid signal corresponding to the enzyme of low xanthine oxidase activity and a slow signal indicating a significant content of desulpho-form. Resulphuration experiments, together with calculations based on enzymic activity and Mo content, led to an estimate of 50-60% desulpho-form. Fe/S EPR showed, in addition to the well-known Fe/S I and Fe/S II species, the presence of a third Fe/S signal, named Fe/S III, which appears to replace partially Fe/S I. Comparison is made with similarly prepared bovine milk XOR, which has approx. 15-fold higher enzymic activity and Mo content. Taken along with evidence of low Mo content in the milk of other mammals, these findings add further support to the idea that XOR protein plays a physiological role in milk (e.g. in secretion) equal in importance to its catalytic function as an enzyme.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15679468      PMCID: PMC1138957          DOI: 10.1042/BJ20041984

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  43 in total

Review 1.  Role of xanthine oxidoreductase as an antimicrobial agent.

Authors:  Hannah M Martin; John T Hancock; Vyv Salisbury; Roger Harrison
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

2.  Purification of the bovine xanthine oxidoreductase from milk fat globule membranes and cloning of complementary deoxyribonucleic acid.

Authors:  L Berglund; J T Rasmussen; M D Andersen; M S Rasmussen; T E Petersen
Journal:  J Dairy Sci       Date:  1996-02       Impact factor: 4.034

3.  > or = 95% of xanthine oxidase in human milk is present as the demolybdo form, lacking molybdopterin.

Authors:  B Godber; S Sanders; R Harrison; R Eisenthal; R C Bray
Journal:  Biochem Soc Trans       Date:  1997-08       Impact factor: 5.407

4.  Expression of Drosophila melanogaster xanthine dehydrogenase in Aspergillus nidulans and some properties of the recombinant enzyme.

Authors:  Benjamin Adams; David J Lowe; Andrew T Smith; Claudio Scazzocchio; Stephane Demais; Robert C Bray
Journal:  Biochem J       Date:  2002-02-15       Impact factor: 3.857

5.  Molecular activation-deactivation of xanthine oxidase in human milk.

Authors:  A M Brown; M Benboubetra; M Ellison; D Powell; J D Reckless; R Harrison
Journal:  Biochim Biophys Acta       Date:  1995-10-19

6.  Sequence motif-specific assignment of two [2Fe-2S] clusters in rat xanthine oxidoreductase studied by site-directed mutagenesis.

Authors:  T Iwasaki; K Okamoto; T Nishino; J Mizushima; H Hori
Journal:  J Biochem       Date:  2000-05       Impact factor: 3.387

7.  Xanthine oxidase from human liver: purification and characterization.

Authors:  T A Krenitsky; T Spector; W W Hall
Journal:  Arch Biochem Biophys       Date:  1986-05-15       Impact factor: 4.013

Review 8.  Structure and function of xanthine oxidoreductase: where are we now?

Authors:  Roger Harrison
Journal:  Free Radic Biol Med       Date:  2002-09-15       Impact factor: 7.376

Review 9.  The physiology of endothelial xanthine oxidase: from urate catabolism to reperfusion injury to inflammatory signal transduction.

Authors:  Avedis Meneshian; Gregory B Bulkley
Journal:  Microcirculation       Date:  2002-07       Impact factor: 2.628

10.  Organ distribution and molecular forms of human xanthine dehydrogenase/xanthine oxidase protein.

Authors:  A Sarnesto; N Linder; K O Raivio
Journal:  Lab Invest       Date:  1996-01       Impact factor: 5.662

View more
  7 in total

1.  The role of human xanthine oxidoreductase (HXOR), anti-HXOR antibodies, and microorganisms in synovial fluid of patients with joint inflammation.

Authors:  Najah Al-Muhtaseb; Elham Al-Kaissi; Abdul Jalil Thawaini; Zuhair Muhi Eldeen; Sabah Al-Muhtaseb; Badiee Al-Saleh
Journal:  Rheumatol Int       Date:  2011-06-05       Impact factor: 2.631

Review 2.  Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol.

Authors:  Pál Pacher; Alex Nivorozhkin; Csaba Szabó
Journal:  Pharmacol Rev       Date:  2006-03       Impact factor: 25.468

3.  Biochemical measurement of neonatal hypoxia.

Authors:  Megan S Plank; Teleka C Calderon; Yayesh Asmerom; Danilo S Boskovic; Danilyn M Angeles
Journal:  J Vis Exp       Date:  2011-08-24       Impact factor: 1.355

4.  Allopurinol and global left myocardial function in heart failure patients.

Authors:  Gamela Nasr; Cherine Maurice
Journal:  J Cardiovasc Dis Res       Date:  2010-10

Review 5.  Mechanistic insights into xanthine oxidoreductase from development studies of candidate drugs to treat hyperuricemia and gout.

Authors:  Takeshi Nishino; Ken Okamoto
Journal:  J Biol Inorg Chem       Date:  2014-12-12       Impact factor: 3.358

6.  Site directed mutagenesis of amino acid residues at the active site of mouse aldehyde oxidase AOX1.

Authors:  Silvia Schumann; Mineko Terao; Enrico Garattini; Miguel Saggu; Friedhelm Lendzian; Peter Hildebrandt; Silke Leimkühler
Journal:  PLoS One       Date:  2009-04-29       Impact factor: 3.240

7.  Structural and functional insights into the catalytic inactivity of the major fraction of buffalo milk xanthine oxidoreductase.

Authors:  Kaustubh S Gadave; Santanu Panda; Surender Singh; Shalini Kalra; Dhruba Malakar; Ashok K Mohanty; Jai K Kaushik
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.